STOCK TITAN

Director at Abbott (NYSE: ABT) buys 2,000 shares in open market

Filing Impact
(Moderate)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Abbott Laboratories director John G. Stratton reported an open-market purchase of 2,000 common shares on May 7, 2026 at a price of $86.82 per share. Following this transaction, he directly owns 23,319 common shares of Abbott Laboratories.

Positive

  • None.

Negative

  • None.
Insider Stratton John G
Role null
Bought 2,000 shs ($174K)
Type Security Shares Price Value
Purchase Common shares without par value 2,000 $86.82 $174K
Holdings After Transaction: Common shares without par value — 23,319 shares (Direct, null)
Footnotes (1)
Shares purchased 2,000 shares Open-market purchase on May 7, 2026
Purchase price $86.82 per share Open-market buy of Abbott common shares
Shares owned after transaction 23,319 shares Director’s direct holdings following the purchase
Buy transactions in filing 1 transaction Form 4 transaction summary buyCount
Net buy/sell shares 2,000 shares net-buy Form 4 transactionSummary netBuySellShares
open-market purchase financial
"transaction_action: "open-market purchase" for 2,000 common shares"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
Common shares without par value financial
"security_title: "Common shares without par value""
Form 4 regulatory
"INSIDER FILING DATA (Form 4) describing the transaction"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
direct ownership financial
"direct_or_indirect: "D" and ownership_type: "direct""
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Stratton John G

(Last)(First)(Middle)
100 ABBOTT PARK ROAD

(Street)
ABBOTT PARK ILLINOIS 60064

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common shares without par value05/07/2026P2,000A$86.8223,319D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
/s/ John G. Stratton by Jessica H. Paik, Attorney-in-Fact06/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Abbott Laboratories (ABT) report?

Abbott Laboratories reported that director John G. Stratton made an open-market purchase of 2,000 common shares. The transaction took place on May 7, 2026, and was reported on a Form 4 insider trading filing.

How many Abbott (ABT) shares did John G. Stratton buy and at what price?

John G. Stratton bought 2,000 Abbott common shares at a price of $86.82 per share. This was an open-market purchase, indicating he directly acquired the stock on the market rather than through a grant or option exercise.

What are John G. Stratton’s total Abbott (ABT) holdings after the transaction?

After the reported purchase, John G. Stratton directly owns 23,319 Abbott common shares. This total reflects his position immediately following the 2,000-share open-market buy disclosed in the Form 4 filing.

Was the Abbott (ABT) insider transaction a purchase or a sale?

The insider transaction was a purchase. The Form 4 lists a transaction code “P” and describes it as an open-market purchase of 2,000 Abbott common shares at $86.82 per share, increasing the director’s direct holdings.

Does the Abbott (ABT) Form 4 involve any derivative securities or options?

No, the Form 4 shows only a non-derivative transaction in common shares without par value. The derivativeSummary section is empty, indicating no reported option exercises, conversions, or other derivative-related activities in this filing.

Is John G. Stratton’s Abbott (ABT) ownership direct or indirect?

John G. Stratton’s reported ownership in this filing is direct. The transaction is coded as direct ownership, and the nature of ownership field does not indicate any trust, LLC, or other indirect holding structure for these 23,319 common shares.